Approximately 10% of babies need help to start breathing, and 1% of all babies born need extensive resuscitation to try and save their lives. Currently, attending medical staff have a choice of methods to help newborns begin breathing – they can use a mask with either a selfinflating or a mechanically-inflating bag fitted to it, or they can use a T-piece resuscitator (TPR) to mechanically pump air into the baby’s lungs. The bag methods provide Positive Pressure Ventilation (PPV), to force the lungs open; the TPR can provide PPV, but also has the ability to provide Continuous Positive Air Pressure (CPAP), which means residual air is left in the lungs to prevent them collapsing between breaths. However, the TPR can only provide PPV or CPAP one at a time, not both simultaneously. A small trial has demonstrated the therapeutic potential of a new device, composed of a generator and a driver, which is able to provide both PPV and CPAP simultaneously. No other device is available on the market that is able to provide this PPV/CPAP functionality concurrently. This innovative technology contains other novel features, such as a dual pressure gauge, and the ability for a mask or prong to deliver the airflow to the baby. This project will develop and test these prototype models (components of which are already patented) into fully-functioning, CE-marked, production-ready units. These will then be sold into the global neonatal healthcare market. The device works in a very similar way to existing resuscitation devices, so minimal training will be needed for medical staff, allowing a rapid marketplace uptake. This device could well become the gold standard of treatment for newborn resuscitation. It will save more lives, prevent the physical injuries caused by other methods of neonatal resuscitation, and lowering the incidence of permanent damage caused by lack of oxygen at birth.